Key Highlights

  • 8.20% is the indicated pre-market decline for IN8bio, Inc. (NASDAQ:INAB) on November 17, 2026, taking the price to USD 0.7491 from a calculated prior close of USD 0.8160, a calculated move of -USD 0.0669.
  • 7.39 million is the calculated market Capitalization in USD, based on 9.86 million shares outstanding and the indicated price of USD 0.7491, which places the clinical-stage company in nano-cap territory with elevated Volatility and dilution risk.
  • 17.96 million is the USD cash and short-term Investment balance at June 30, 2026, down from USD 21.94 million in March 2026, against Debt of USD 2.18 million and a quarterly net loss of USD 4.78 million.
  • 18.67 million is the USD trailing net loss, equal to USD 1.48 per share, for a gamma-delta T cell therapy developer whose lead candidates target glioblastoma and other cancers, and which has no reported revenue.

What Moved IN8bio, Inc. (NASDAQ:INAB) in Pre-Market Trading on November 17, 2026 (-USD 0.0669, -8.20%)

The indicated pre-market price for IN8bio, Inc. (NASDAQ:INAB) is USD 0.7491 on November 17, 2026, a pre-market move of -8.20%. The calculated prior close is USD 0.8160 (USD 0.7491 divided by 0.9180), and the calculated USD move is -USD 0.0669. Using 9.86 million shares outstanding, the calculated market capitalization is about USD 7.39 million. Published market data showed a price of USD 1.065 on October 22, 2026 and a 52-week range of USD 0.88 to USD 2.73, so the indicated price is below that earlier low. Pre-market Volume was not found.

The Rationale: No Single Catalyst Identified for the Decline in IN8bio, Inc. (NASDAQ:INAB)

No catalyst for the November 17, 2026 decline was identified in published coverage. As general context, a sub-USD 1.00 clinical-stage stock can drift lower as short-term holders sell, and pre-market illiquidity widens swings. Company news in 2026 included updated overall survival data at ASCO 2026 on June 1, a Nature Communications publication on June 3, a Journal of Clinical Oncology publication on July 9, the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research and Development on September 9, and an inducement grant reported October 6, 2026.

Valuation, Liquidity and Risks for IN8bio, Inc. (NASDAQ:INAB)

IN8bio is developing gamma-delta T cell therapies for cancer and autoimmune diseases, led by INB-400 in a Phase 2 study in newly diagnosed glioblastoma, INB-200 in Phase 1 and the allogeneic INB-100 in Phase 1. Net loss was USD 4.78 million for the June 2026 quarter and USD 5.09 million for the March 2026 quarter. At June 30, 2026, total Assets were USD 21.75 million and shareholders' Equity was USD 18.36 million. Cash covers about 3.8 quarters of the latest quarterly loss (calculated). With a price below USD 1.00, Nasdaq minimum bid rules, dilution and clinical risks are relevant, though no notice was found.

Where Things Stand

IN8bio, Inc. (NASDAQ:INAB) is indicated down 8.20% in pre-market trading on November 17, 2026, at USD 0.7491, a calculated decline of USD 0.0669 from a prior close of USD 0.8160. No specific catalyst was identified in published coverage. The calculated market capitalization is about USD 7.39 million on 9.86 million shares, cash was USD 17.96 million at June 30, 2026 and the trailing net loss was USD 18.67 million. Clinical timelines, financing needs and Nasdaq bid price rules remain central risks, and pre-market moves in thinly traded nano-caps can reverse quickly. This article is informational and is not investment advice.